Artan Biotechnologies LLC has closed a $1 million seed round to support progression of the company’s proprietary mutation-specific codon suppression platform toward first-in-human development.

Artan Biotechnologies LLC has completed a $200,000 seed raise to fund preclinical advancement of the company’s proprietary engineered suppressor platform, which targets nonsense mutations.

Protuoso Biosciences has announced the close of an oversubscribed $9.5 million seed financing round, the proceeds of which will be used to advance its multifunctional protein engineering platform and broad pipeline across cardiometabolic, oncology and autoimmune diseases.

Reprogram Biosciences Inc., a preclinical oncology biotechnology company developing mRNA-based therapeutics to treat solid tumors, has announced the close of its seed financing, bringing the total capital raised to $6 million since the company’s founding in 2025.

Re-Aim Therapeutics Ltd. has launched with £7 million (US$9.4 million) in seed investment backing and a focus on developing functional cures for T-cell-mediated autoimmune diseases.

Scarlet Therapeutics Ltd. has demonstrated its manufactured red blood cells (RBCs) act in the same way as their natural counterparts in vivo, opening the way for the cells to be used as drug delivery vehicles and raising the possibility they could replace conventional blood transfusions. To build on this, Scarlet has closed a $4 million seed round to work on the first clinical application, in which RBCs loaded with therapeutic proteins will be used to treat rare metabolic diseases.

Parcelbio has raised $13 million in seed financing to continue its development of a new class of potent and durable mRNA medicines. The financing will support development of Parcelbio’s proprietary APEXm (Amplified and Prolonged EXpression mRNA) platform and advance its pipeline, including its lead in vivo CAR T program for autoimmune disease.

Signadori Bio SAS has successfully completed its seed extension financing round, bringing to €11.1 million (US$13 million) the total raised to support its development of a next-generation, off-the-shelf, in vivo-engineered, monocyte immunotherapy platform to treat solid tumors.

Ferrosa Therapeutics AG has announced a $3.5 million seed financing to support the development of a first-in-class bispecific antibody (FRS-101) to treat anemia of inflammation across chronic kidney disease, autoimmune disease and oncology indications.